SWM
UNCY icon

Spire Wealth Management’s Unicycive Therapeutics UNCY Stock Holding History

Spire Wealth Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$1K – 2596
2022
Q2 		$1K Buy
+100
New +$955 ﹤0.01% 2586

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Spire Wealth Management's UNCY Position: Q3 2022 in Review

Spire Wealth Management sold out of Unicycive Therapeutics (UNCY) in Q3 2022, closing a stake of 100 shares — an estimated $1K sold.

Spire Wealth Management first reported a position in UNCY in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 12 funds tracked by Wall St. Rank hold UNCY as of Q3 2022.

  • Spire Wealth Management reported no remaining Unicycive Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Spire Wealth Management sold 100 Unicycive Therapeutics shares in Q3 2022, an estimated $1K.
  • Spire Wealth Management first reported a position in Unicycive Therapeutics in Q2 2022 and held it in 1 quarter.
  • Spire Wealth Management's Unicycive Therapeutics position peaked at $1K in Q2 2022.
  • 12 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.